Connect with us

Technology

OPPI Annual Summit Presents the Roadmap on Becoming the Pharma Powerhouse to the World

Published

on

This year’s Summit theme, ‘Viksit Bharat@2047’, envisions India’s journey from the Pharmacy of the World to a Global Pharma Powerhouse, advancing inclusive healthcare and innovation for a developed India 

NEW DELHI, Nov. 28, 2024 /PRNewswire/ — The Organisation of Pharmaceutical Producers of India (OPPI) organized its flagship Annual Summit today, at The Lalit, New Delhi. The summit brought together a distinguished assembly of key Government officials, regulators, industry leaders, member organisations, academia, patient support groups, innovators and other key stakeholders. Centered around the theme Viksit Bharat @2047 — India’s Path from the ‘Pharmacy of the World’ to the ‘Pharma Powerhouse to the World’, the summit set forth the vision for India’s healthcare evolution. The platform witnessed deliberations on pivotal topics, including innovation, skills development and technology, with a strong focus on advancing accessible and high-quality healthcare services across the nation.

Bhushan Akshikar, President, OPPI, Vice President & Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said, “As we work towards an inclusive, innovative and sustainable healthcare future for India, OPPI remains committed to our vision of Bharat Ke Liye, delivering accessible, high-quality healthcare solutions to Indian patients. As an industry, we are committed to collaborating with all ecosystem partners to deliver impactful solutions not only for today but also lay the groundwork for India’s emergence as a global leader in pharma for tomorrow. Together, we are shaping a future where healthcare is accessible and transformative for all.” 

Anil Matai, Director General, OPPI, said, “The OPPI Annual Summit celebrates the pharmaceutical sector’s dedication to innovation and excellence, embodying our shared vision for a robust healthcare ecosystem where advancements are matched with patient centricity. India stands at the cusp of a remarkable transformation in healthcare, and the pharmaceutical industry is set to play a pivotal role in realizing the vision of Viksit Bharat@2047. By leveraging our strengths in innovation, we can evolve from being the ‘Pharmacy of the World’ to a true global pharma powerhouse. Moving forward, we must continue fostering an environment that values research, innovation and resilient healthcare infrastructure. This summit is a great platform to explore how we, as a community of industry leaders, can build on this legacy and propel India to new heights in delivering safe and advanced healthcare solutions to the world.” 

The summit also witnessed the launch of reports and informative booklets, ‘Viksit Bharat@2047 — Transforming India from Pharmacy of the World to Pharma Powerhouse to the World’, in collaboration with EY, and ‘Winning in Indian Healthcare’, in collaboration with BCG. Additionally, informative booklets on ‘Over the Counter (OTC) Drugs’ and the ‘Value of Innovation’ were released, highlighting the significance of innovation and creating awareness on OTC drugs.

The EY-OPPI report, titled Viksit Bharat@2047 — Transforming India from Pharmacy of the World to Pharma Powerhouse to the World, highlights the key growth imperatives required for India’s pharmaceutical sector to become a global powerhouse. It envisions a resilient, inclusive healthcare ecosystem where policymakers, providers, pharma companies and patient advocates collaborate to elevate patient care. Achieving these goals will position India’s healthcare model as a beacon of innovation and equitable access for the world.

As India’s pharmaceutical market gears for transformative growth, the ‘Winning in Indian Healthcare‘ report by BCG and OPPI explores the dynamic forces reshaping this critical sector. Against the backdrop of rapid economic growth, streamlined government policies, and digital health innovations, the report unpacks India’s unique healthcare potential. It highlights the drivers for growth (rising demand driven by an aging population, a burgeoning middle class, and a chronic disease burden), alongside challenges such as regulatory complexities, fragmented payer coverage, and market complexities. To thrive in this evolving landscape, global pharma players must rethink the portfolio strategy, invest in access initiatives, and embrace wider ecosystem partnerships. This report serves as a strategic guide for navigating India’s vibrant but challenging healthcare ecosystem.

The bilingual FAQs (in Hindi and English) on the Value of Innovation emphasize the critical role of R&D and innovation in the biopharmaceutical sector, touching on the costs and timelines associated with drug development and the importance of strengthening the Intellectual Property Rights (IPR) framework.

Another important release was the FAQs on Over the Counter (OTC) Drugs in India, which highlights the rapid rise of OTC drug adoption, especially in the context of chronic and lifestyle diseases like diabetes and cardiovascular conditions. This shift toward proactive, self-managed healthcare is pivotal in improving public health outcomes while optimizing healthcare resource utilization.

The summit’s discussions spanned diverse dimensions, covering key themes such as:

Winning in Indian Healthcare: The impact of Global Pharma companies on Indian Healthcare and the Road AheadViksit Bharat @2047: Transforming India from Pharmacy of the World to Pharma Powerhouse to The WorldCollaborative Strategies: To Improve Access to Healthcare in India

The exceptional contributors and innovators in the healthcare sector were celebrated and recognized with the prestigious OPPI Awards. These awards honoured excellence, innovation, and a steadfast commitment to enhancing healthcare in Bharat. The esteemed awardees for 2024 included:

OPPI Lifetime Achievement Award 2024

Dr Gullapalli N. Rao, Founder Chair, L V Prasad Eye Institute 

 

OPPI Scientist Award 2024

Scientist of the Year

Dr Arun Kumar Shukla, Professor and Sonu Agrawal Memorial Chair, Indian Institute of Technology, Kanpur

Woman Scientist of the Year

Prajakta Dandekar Jain, Co-ordinator, M.Tech. Pharmaceutical Biotechnology Program, UGC Assistant Professor in Engineering Sciences, Institute of Chemical Technology, Mumbai

Young Scientist of the Year

Rachit Agarwal, Associate Professor, Indian Institute of Science

 

OPPI Excellence in Innovation Healthcare Start-up of the Year 2024

Neodocs

About OPPI 

The Organisation of Pharmaceutical Producers of India (OPPI), established in 1965, represents the research-based global pharmaceutical companies in India. OPPI has been an integral part of the healthcare journey of the country. We remain committed to supporting the nation’s healthcare objectives, putting patients at the core of all decision making and collaborating with all stakeholders to find sustainable solutions to realize the collective vision of Health for All.

Our member companies have been serving the country’s healthcare ecosystem since pre-independence and continue to remain committed to patient safety and providing quality care in the future as well. As an association, our advocacy decisions, patient commitment and work are always keeping the country first, and we embody the spirit of working for ‘Bharat Ke Liye‘; driven with innovation to find solutions for unmet medical needs, collaboration with Government stakeholders, and co-creation with partners coming together to address the nation’s healthcare challenges. We are committed to the Hon’ble Prime Minister Shri Narendra Modi-ji’s clarion call of ‘Jai Vigyan and Jai Anusandhan’.

The reports can be accessed here:

Viksit Bharat@2047 – Transforming India from Pharmacy of the World to Pharma Powerhouse to the World
Winning in Indian Healthcare
Value of Innovation (in Hindi and English)
Over the Counter (OTC) Drugs in India

Photo: https://mma.prnewswire.com/media/2569307/OPPI_Annual_Summit.jpg
Logo: https://mma.prnewswire.com/media/2569306/OPPI_Logo.jpg

 

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/oppi-annual-summit-presents-the-roadmap-on-becoming-the-pharma-powerhouse-to-the-world-302318291.html

Continue Reading

Technology

3M announces collaboration with GSEO to advance Expanded Beam Optical manufacturing and development

Published

on

By

ST. PAUL, Minn., Oct. 19, 2026 /PRNewswire/ — 3M (NYSE: MMM) today announced a collaboration with Genius Electronic Optical Co., Ltd. (GSEO, Taiwan: 3406), an optical technology company, to advance technology development and manufacturing for 3M’s Expanded Beam Optical (EBO) solutions. In support of these efforts, 3M expects to make a strategic investment to acquire approximately 4.7% of GSEO’s common shares as part of the company’s private placement of newly issued shares, subject to customary closing conditions.

The collaboration brings together 3M’s EBO technology leadership, optical interconnect expertise, materials science, manufacturing scale and customer relationships with GSEO’s precision optics manufacturing capabilities and production scale. Together, the companies aim to support EBO commercialization and long-term capacity expansion to meet growing demand from hyperscale data centers and other advanced connectivity applications.

“3M is investing in capabilities and partnerships that can accelerate innovation for our customers,” said William Brown, 3M Chairman and CEO. “By selecting GSEO as a manufacturing partner and investing in the company, we are strengthening the path to scale next-generation optical connectivity solutions for high-performance data center infrastructure.”

GSEO’s existing precision optics manufacturing capabilities and technical development experience are expected to support manufacturing readiness for 3M’s EBO ferrules, co-packaged optics solutions and related optical interconnect applications. The collaboration is part of 3M’s broader EBO ecosystem strategy, which includes continued work with customers and partners across the optical interconnect market.

“GSEO is pleased to expand its relationship with 3M as we work together to advance optical interconnect solutions for next-generation data center infrastructure,” said Micro Kuo, GSEO CEO and President. “This collaboration brings together complementary technology and manufacturing strengths to support continued innovation and help meet the performance demands of high-growth connectivity markets.”

3M expects the strategic investment to close in the fourth quarter of 2026, subject to customary closing conditions.

Forward-Looking Statements
Certain statements in this release are considered “forward-looking statements” under the federal securities laws, including the Private Securities Litigation Reform Act of 1995, as amended, and are intended to enjoy the protection of those laws. Forward-looking statements may appear throughout this release and are typically identified by the words “aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “evaluate,” “expect,” “forecast,” “future,” “goal,” “guidance,” “impact,” “initial,” “intend,” “likely,” “may,” “outlook,” “plan,” “possible,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “strategy,” “target,” “will,” “would,” and other words that are similar to, or have the opposite meanings of, those words. Forward-looking statements speak only as of the date they are made, 3M assumes no duty to update those statements, and readers are cautioned not to place undue reliance on any of those statements. Forward-looking statements are based on certain assumptions and expectations of future events and trends that are subject to risks and uncertainties, including those described in Part I, Item 1A, “Risk Factors” of 3M’s Form 10-K for the year ended December 31, 2025.

About 3M
3M (NYSE: MMM) is focused on transforming industries around the world by applying science and creating innovative, customer-focused solutions. Our multi-disciplinary team is working to solve tough customer problems by leveraging diverse technology platforms, differentiated capabilities, global footprint, and operational excellence. Discover how 3M is shaping the future at 3M.com/news.

Contacts
3M
Investor Contact:
Diane Farrow, 612-202-2449
Media Contact:
3MNews@mmm.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/3m-announces-collaboration-with-gseo-to-advance-expanded-beam-optical-manufacturing-and-development-302913170.html

SOURCE 3M Company

Continue Reading

Technology

Scott Vicknair Personal Injury Lawyers Announces Second Annual Operation Fur-Ever Home Pet Adoption Event at Lafreniere Park

Published

on

By

NEW ORLEANS, Oct. 19, 2026 /PRNewswire/ — Scott Vicknair Personal Injury Lawyers is excited to announce the return of its second annual Operation Fur-Ever Home, a free community pet adoption event taking place on Saturday, November 14, 2026, from 9:00 a.m. to 11:00 a.m. at Lafreniere Park in Metairie, Louisiana.

The free, family-friendly event will give attendees the opportunity to meet adoptable pets from local animal shelters, learn about responsible pet ownership, and potentially welcome a new furry companion into their homes. Those who preregister for the event will also be entered for a chance to win a Soundcore speaker and a free pet adoption.

“Last year’s event was everything we hoped it would be, and we are incredibly excited to bring Operation Fur-Ever Home back for a second year,” said David Vicknair, founding partner of Scott Vicknair Personal Injury Lawyers. “There is something special about watching a family meet a pet that could become part of their lives for years to come. We wanted to create another opportunity to make those connections while supporting the organizations that work tirelessly to care for animals in our community.”

Building on the success of the first event, this year’s event continues the firm’s commitment to supporting local animal shelters and creating meaningful opportunities for families throughout Southeast Louisiana.

“Giving back to our community has always been an important part of who we are as a firm,” said Vicknair. “Whether we are helping students prepare for school, recognizing deserving teachers, or supporting local animal shelters, our goal is to make a positive difference in the communities we serve.”

Operation Fur-Ever Home is free and open to the public. Families, animal lovers, and anyone interested in adopting a pet are encouraged to attend and preregister.

About Scott Vicknair Personal Injury Lawyers

Scott Vicknair Personal Injury Lawyers is a New Orleans-based personal injury firm committed to providing exceptional legal representation while also investing in the communities it serves. Their experienced team of dedicated attorneys specializes in car accidents, personal injury, and wrongful death cases in New Orleans. With diverse personal and professional backgrounds, they craft legal strategies tailored to each client’s specific case and needs.

View original content:https://www.prnewswire.com/news-releases/scott-vicknair-personal-injury-lawyers-announces-second-annual-operation-fur-ever-home-pet-adoption-event-at-lafreniere-park-302913183.html

SOURCE Scott Vicknair Personal Injury Lawyers

Continue Reading

Technology

Can we produce low-cost omega-3s without relying on fish?

Published

on

By

GOLD COAST, Australia, Oct. 19, 2026 /PRNewswire/ — Southern Cross University researchers are aiming to halve the cost of producing omega-3 supplements to make these essential nutrients more accessible to pregnant women and infants in low-income countries, backed by the University’s first-ever grant from The Gates Foundation.

The research takes a novel approach: rather than relying on fish oil, the team is going closer to the original source of omega-3. Fish don’t produce omega-3 themselves – they accumulate it from marine microorganisms lower in the food chain.

Led by Professor Dirk Erler from Southern Cross University’s Faculty of Science and Engineering, the team is investigating how these naturally omega-3-producing microorganisms can be grown more cheaply through precision fermentation, including the use of agricultural and food-processing by-products as a source of fermentation sugar.

Omega-3 is an important nutrient during pregnancy and early life, supporting brain and nervous system development in babies. But the cost of supplements remains a significant barrier to access in many low-income countries.

“The main barrier for the uptake of omega-3s as supplements in pregnant women is the cost,” Professor Erler said.

“The whole objective of our project is to reduce that cost and make omega-3 supplements more available.”

The research team at Southern Cross University, which includes biomedical scientist Dr Nedeljka Rosic, Dr Shane McIntosh, postdoctoral researcher Dr Jasmine Haskell and PhD researcher Michael Ingram, is focused on growing omega-3-producing marine microorganisms known as thraustochytrids – or ‘throstys’ for short.

“By growing those microorganisms on land through precision fermentation, we have an alternative way of producing omega-3s that is both reliable and highly targeted,” Professor Erler said.

Precision fermentation allows the researchers to grow thraustochytrids under controlled conditions to produce omega-3 oils. The team is investigating whether expensive feedstocks used in the process can be replaced with lower-cost agricultural and food-processing by-products, helping drive down the overall cost of production.

The approach could also reduce reliance on wild-caught fish as a source of omega-3 oil and create a more reliable, scalable, and local supply.

For biomedical scientist Dr Nedeljka Rosic, the production challenge is ultimately about what greater access to omega-3 could mean for women and babies.

“As a biomedical scientist, my purpose is to find ways to use science to improve people’s health,” Dr Rosic said.

“This project is important because it aims to improve the health of pregnant women and children and reduce preterm births through simple dietary improvements.”

View original content to download multimedia:https://www.prnewswire.com/news-releases/can-we-produce-low-cost-omega-3s-without-relying-on-fish-302893631.html

SOURCE Southern Cross University

Continue Reading

Trending